- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT03939481
항암화학요법으로 유발된 암환자의 말초신경병증 발생에 대한 치료 효과
암 환자의 탁산 유발 말초 신경병증의 예측 모델 개발을 위한 전향적 관찰 코호트 연구
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
연구 개요
상태
정황
- 해부학적 1기 유방암 AJCC v8
- 해부학적 IA기 유방암 AJCC v8
- 해부학적 IB기 유방암 AJCC v8
- 해부학적 II기 유방암 AJCC v8
- 해부학적 IIA기 유방암 AJCC v8
- 해부학적 IIB기 유방암 AJCC v8
- 해부학적 III기 유방암 AJCC v8
- 해부학적 IIIA기 유방암 AJCC v8
- 해부학적 IIIB기 유방암 AJCC v8
- 해부학적 병기 IIIC 유방암 AJCC v8
- 예후 I기 유방암 AJCC v8
- 예후 IA기 유방암 AJCC v8
- 예후 IB기 유방암 AJCC v8
- 예후 II기 유방암 AJCC v8
- 예후 IIA기 유방암 AJCC v8
- 예후 IIB기 유방암 AJCC v8
- 예후 III기 유방암 AJCC v8
- 예후 IIIA기 유방암 AJCC v8
- 예후 IIIB기 유방암 AJCC v8
- 예후 IIIC기 유방암 AJCC v8
- 폐 비소세포 암종
- 3기 폐암 AJCC v8
- II기 폐암 AJCC v8
- IIA기 폐암 AJCC v8
- IIB기 폐암 AJCC v8
- IIIA기 폐암 AJCC v8
- IIIB기 폐암 AJCC v8
- 1기 폐암 AJCC v8
- IA1기 폐암 AJCC v8
- IA2기 폐암 AJCC v8
- IA3기 폐암 AJCC v8
- IB기 폐암 AJCC v8
- IIIC기 폐암 AJCC v8
- 3기 난소암 AJCC v8
- IIIA기 난소암 AJCC v8
- IIIA1기 난소암 AJCC v8
- IIIA2기 난소암 AJCC v8
- IIIB기 난소암 AJCC v8
- IIIC기 난소암 AJCC v8
- 2기 난소암 AJCC v8
- IIA기 난소암 AJCC v8
- IIB기 난소암 AJCC v8
- 1기 난소암 AJCC v8
- IA기 난소암 AJCC v8
- IB기 난소암 AJCC v8
- 병기 IC 난소암 AJCC v8
상세 설명
PRIMARY OBJECTIVES:
I. To develop and validate a clinical risk prediction model using clinical factors for the development of peripheral neuropathy in patients receiving taxane-based chemotherapy regimens.
SECONDARY OBJECTIVES:
I. To examine patient-reported outcomes (PROs) and objective measures of chemotherapy induced peripheral neuropathy (CIPN) to better define the phenotype of peripheral neuropathy in this patient population.
II. To assess the incidence of CIPN within one year in this patient population. III. To identify predictors of treatment dose reductions, delays, and discontinuations associated with CIPN symptoms in this patient population.
OTHER OBJECTIVES:
I. To collect serum and plasma samples for future testing for biomarker and mechanistic studies of CIPN.
OUTLINE:
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Tlalpan
-
Mexico City, Tlalpan, 멕시코, 14080
- Instituto Nacional De Cancerologia de Mexico
-
-
-
-
California
-
Antioch, California, 미국, 94531
- Kaiser Permanente-Deer Valley Medical Center
-
Dublin, California, 미국, 94568
- Kaiser Permanente Dublin
-
Fremont, California, 미국, 94538
- Kaiser Permanente-Fremont
-
Fresno, California, 미국, 93720
- Kaiser Permanente-Fresno
-
Oakland, California, 미국, 94611
- Kaiser Permanente-Oakland
-
Palm Springs, California, 미국, 92262
- Desert Regional Medical Center
-
San Francisco, California, 미국, 94115
- Kaiser Permanente-San Francisco
-
San Jose, California, 미국, 95119
- Kaiser Permanente-Santa Teresa-San Jose
-
San Leandro, California, 미국, 94577
- Kaiser Permanente San Leandro
-
San Rafael, California, 미국, 94903
- Kaiser San Rafael-Gallinas
-
Santa Clara, California, 미국, 95051
- Kaiser Permanente Medical Center - Santa Clara
-
Santa Rosa, California, 미국, 95403
- Kaiser Permanente-Santa Rosa
-
Vacaville, California, 미국, 95688
- Kaiser Permanente Medical Center-Vacaville
-
Vallejo, California, 미국, 94589
- Kaiser Permanente-Vallejo
-
Walnut Creek, California, 미국, 94596
- Kaiser Permanente-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, 미국, 80045
- Rocky Mountain Regional VA Medical Center
-
-
Delaware
-
Dover, Delaware, 미국, 19901
- Bayhealth Hospital Kent Campus
-
Milford, Delaware, 미국, 19963
- Bayhealth Hospital Sussex Campus
-
-
Florida
-
Fort Myers, Florida, 미국, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Fort Myers, Florida, 미국, 33905
- Florida Gynecologic Oncology
-
Pensacola, Florida, 미국, 32504
- Sacred Heart Hospital
-
-
Georgia
-
Savannah, Georgia, 미국, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Hawaii
-
Honolulu, Hawaii, 미국, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, 미국, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, 미국, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, 미국, 96826
- Kapiolani Medical Center for Women and Children
-
Honolulu, Hawaii, 미국, 96819
- Kaiser Permanente Moanalua Medical Center
-
Lihue, Hawaii, 미국, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
‘Aiea, Hawaii, 미국, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, 미국, 96701
- Hawaii Cancer Care - Savio
-
-
Illinois
-
Centralia, Illinois, 미국, 62801
- Centralia Oncology Clinic
-
Danville, Illinois, 미국, 61832
- Carle on Vermilion
-
Decatur, Illinois, 미국, 62526
- Decatur Memorial Hospital
-
Decatur, Illinois, 미국, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Effingham, Illinois, 미국, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, 미국, 62401
- Carle Physician Group-Effingham
-
Evergreen Park, Illinois, 미국, 60805
- Little Company of Mary Hospital
-
Hines, Illinois, 미국, 60141
- Edward Hines Jr VA Hospital
-
Mattoon, Illinois, 미국, 61938
- Carle Physician Group-Mattoon/Charleston
-
Moline, Illinois, 미국, 61265
- Trinity Medical Center
-
O'Fallon, Illinois, 미국, 62269
- Cancer Care Center of O'Fallon
-
Urbana, Illinois, 미국, 61801
- Carle Cancer Center
-
Urbana, Illinois, 미국, 61801
- The Carle Foundation Hospital
-
-
Iowa
-
Ames, Iowa, 미국, 50010
- McFarland Clinic PC - Ames
-
Cedar Rapids, Iowa, 미국, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, 미국, 52403
- Oncology Associates at Mercy Medical Center
-
Cedar Rapids, Iowa, 미국, 52402
- Physicians' Clinic of Iowa PC
-
Clive, Iowa, 미국, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, 미국, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Creston, Iowa, 미국, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, 미국, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, 미국, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, 미국, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, 미국, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, 미국, 50314
- Medical Oncology and Hematology Associates-Laurel
-
West Des Moines, Iowa, 미국, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, 미국, 67601
- HaysMed University of Kansas Health System
-
Lawrence, Kansas, 미국, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, 미국, 66061
- Olathe Health Cancer Center
-
Salina, Kansas, 미국, 67401
- Salina Regional Health Center
-
Topeka, Kansas, 미국, 66606
- University of Kansas Health System Saint Francis Campus
-
Wichita, Kansas, 미국, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, 미국, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, 미국, 67208
- Associates In Womens Health
-
-
Kentucky
-
Bardstown, Kentucky, 미국, 40004
- Flaget Memorial Hospital
-
Lexington, Kentucky, 미국, 40509
- Saint Joseph Hospital East
-
London, Kentucky, 미국, 40741
- Saint Joseph London
-
-
Louisiana
-
New Orleans, Louisiana, 미국, 70112
- Tulane University Health Sciences Center
-
New Orleans, Louisiana, 미국, 70112
- University Medical Center New Orleans
-
New Orleans, Louisiana, 미국, 70112
- Louisiana State University Health Science Center
-
Shreveport, Louisiana, 미국, 71103
- LSU Health Sciences Center at Shreveport
-
-
Maine
-
Augusta, Maine, 미국, 04330
- Harold Alfond Center for Cancer Care
-
Belfast, Maine, 미국, 04915
- Waldo County General Hospital
-
Biddeford, Maine, 미국, 04005
- MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
-
Rockport, Maine, 미국, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, 미국, 04073
- MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
-
Scarborough, Maine, 미국, 04074
- Maine Medical Center- Scarborough Campus
-
-
Maryland
-
Baltimore, Maryland, 미국, 21204
- Greater Baltimore Medical Center
-
Easton, Maryland, 미국, 21601
- University of Maryland Shore Medical Center at Easton
-
-
Massachusetts
-
Burlington, Massachusetts, 미국, 01805
- Lahey Hospital and Medical Center
-
Winchester, Massachusetts, 미국, 01890
- Winchester Hospital
-
-
Michigan
-
Grand Rapids, Michigan, 미국, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, 미국, 49503
- Mercy Health Saint Mary's
-
Reed City, Michigan, 미국, 49677
- Spectrum Health Reed City Hospital
-
Traverse City, Michigan, 미국, 49684
- Munson Medical Center
-
Wyoming, Michigan, 미국, 49519
- Metro Health Hospital
-
-
Minnesota
-
Burnsville, Minnesota, 미국, 55337
- Fairview Ridges Hospital
-
Burnsville, Minnesota, 미국, 55337
- Minnesota Oncology - Burnsville
-
Coon Rapids, Minnesota, 미국, 55433
- Mercy Hospital
-
Deer River, Minnesota, 미국, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, 미국, 55805
- Essentia Health Cancer Center
-
Edina, Minnesota, 미국, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, 미국, 55432
- Unity Hospital
-
Hibbing, Minnesota, 미국, 55746
- Essentia Health Hibbing Clinic
-
Maple Grove, Minnesota, 미국, 55369
- Fairview Clinics and Surgery Center Maple Grove
-
Maplewood, Minnesota, 미국, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, 미국, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, 미국, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, 미국, 55407
- Abbott-Northwestern Hospital
-
Monticello, Minnesota, 미국, 55362
- Monticello Cancer Center
-
Robbinsdale, Minnesota, 미국, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, 미국, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, 미국, 55101
- Regions Hospital
-
Saint Paul, Minnesota, 미국, 55102
- United Hospital
-
Sandstone, Minnesota, 미국, 55072
- Essentia Health Sandstone
-
Stillwater, Minnesota, 미국, 55082
- Lakeview Hospital
-
Virginia, Minnesota, 미국, 55792
- Essentia Health Virginia Clinic
-
Willmar, Minnesota, 미국, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, 미국, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Wyoming, Minnesota, 미국, 55092
- Fairview Lakes Medical Center
-
-
Missouri
-
Rolla, Missouri, 미국, 65401
- Mercy Clinic-Rolla-Cancer and Hematology
-
Springfield, Missouri, 미국, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, 미국, 63131
- Missouri Baptist Medical Center
-
-
Nebraska
-
Grand Island, Nebraska, 미국, 68803
- CHI Health Saint Francis
-
-
New Hampshire
-
Nashua, New Hampshire, 미국, 03060
- Saint Joseph Hospital
-
-
New York
-
New York, New York, 미국, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
North Carolina
-
Asheboro, North Carolina, 미국, 27203
- Randolph Hospital
-
Asheville, North Carolina, 미국, 28803
- AdventHealth Infusion Center Asheville
-
Burlington, North Carolina, 미국, 27215
- Cone Health Cancer Center at Alamance Regional
-
Clinton, North Carolina, 미국, 28328
- Southeastern Medical Oncology Center-Clinton
-
Clyde, North Carolina, 미국, 28721
- AdventHealth Infusion Center Haywood
-
Gastonia, North Carolina, 미국, 28054
- CaroMont Regional Medical Center
-
Goldsboro, North Carolina, 미국, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Greensboro, North Carolina, 미국, 27403
- Cone Health Cancer Center
-
Hendersonville, North Carolina, 미국, 28792
- AdventHealth Hendersonville
-
Jacksonville, North Carolina, 미국, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
New Bern, North Carolina, 미국, 28561
- CarolinaEast Medical Center
-
Pinehurst, North Carolina, 미국, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Rocky Mount, North Carolina, 미국, 27804
- Nash General Hospital
-
Supply, North Carolina, 미국, 28462
- NHRMC Radiation Oncology - Supply
-
Wilmington, North Carolina, 미국, 28401
- New Hanover Regional Medical Center/Zimmer Cancer Center
-
-
North Dakota
-
Minot, North Dakota, 미국, 58701
- Trinity Cancer Care Center
-
-
Ohio
-
Akron, Ohio, 미국, 44307
- Cleveland Clinic Akron General
-
Cincinnati, Ohio, 미국, 45220
- Good Samaritan Hospital - Cincinnati
-
-
Oregon
-
Portland, Oregon, 미국, 97227
- Kaiser Permanente Northwest
-
-
Pennsylvania
-
Phoenixville, Pennsylvania, 미국, 19460
- Phoenixville Hospital
-
-
Rhode Island
-
Warwick, Rhode Island, 미국, 02886
- Kent Hospital
-
-
South Carolina
-
Anderson, South Carolina, 미국, 29621
- AnMed Health Cancer Center
-
Bluffton, South Carolina, 미국, 29910
- Saint Joseph's/Candler - Bluffton Campus
-
Boiling Springs, South Carolina, 미국, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Florence, South Carolina, 미국, 29506
- McLeod Regional Medical Center
-
Gaffney, South Carolina, 미국, 29341
- Gibbs Cancer Center-Gaffney
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, 미국, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, 미국, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, 미국, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, 미국, 29601
- Saint Francis Hospital
-
Greer, South Carolina, 미국, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, 미국, 29651
- Gibbs Cancer Center-Pelham
-
Hilton Head Island, South Carolina, 미국, 29926-3827
- South Carolina Cancer Specialists PC
-
Seneca, South Carolina, 미국, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, 미국, 29303
- Spartanburg Medical Center
-
Union, South Carolina, 미국, 29379
- MGC Hematology Oncology-Union
-
-
Tennessee
-
Cookeville, Tennessee, 미국, 38501
- Cookeville Regional Medical Center
-
Kingsport, Tennessee, 미국, 37660
- Ballad Health Cancer Care - Kingsport
-
-
Texas
-
Lubbock, Texas, 미국, 79415
- UMC Cancer Center / UMC Health System
-
Lubbock, Texas, 미국, 79430
- Texas Tech University Health Sciences Center-Lubbock
-
-
Virginia
-
Bristol, Virginia, 미국, 24201
- Wellmont Medical Associates-Bristol
-
Charlottesville, Virginia, 미국, 22908
- University of Virginia Cancer Center
-
Mechanicsville, Virginia, 미국, 23116
- Bon Secours Memorial Regional Medical Center
-
Midlothian, Virginia, 미국, 23114
- Bon Secours Saint Francis Medical Center
-
Richmond, Virginia, 미국, 23226
- Bon Secours Saint Mary's Hospital
-
-
Washington
-
Issaquah, Washington, 미국, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, 미국, 98368
- Jefferson Healthcare
-
-
Wisconsin
-
Ashland, Wisconsin, 미국, 54806
- Duluth Clinic Ashland
-
New Richmond, Wisconsin, 미국, 54017
- Cancer Center of Western Wisconsin
-
-
-
-
-
Independence, 칠레, 8380455
- Instituto Nacional del Cancer
-
-
-
-
-
Bogotá, 콜롬비아, 99999
- Instituto Nacional De Cancerologia
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Participants with stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer
설명
Inclusion Criteria:
-
Patients must have stage I, II, or III primary non-small cell lung, primary breast, or primary ovarian cancer based on clinical or pathologic evaluation. Patients with Stage IV disease are not eligible.
-
Patients must be planning to start treatment with a taxane-based chemotherapy as part of one of the study-approved taxane regimens (docetaxel chemotherapy regimens for treatment of breast or ovarian cancer, or paclitaxel chemotherapy regimen for treatment of breast, non-small cell lung, or ovarian cancer) within 14 days after registration. (Note that docetaxel or paclitaxel may be administered with a non-neurotoxic chemotherapy, such as cyclophosphamide, and/or biologic agent, such as trastuzumab, and/or carboplatin. Additionally, nab-paclitaxel may not be substituted for paclitaxel for purposes of this study.)
-
Patients who will receive treatment in the setting of any other clinical trial are eligible as long as it is one of the study-approved regimens. Patients may receive additional treatments (i.e., experimental therapy, immunotherapy, biologics, etc.) as part of another clinical trial in addition to any regimen approved in this study.
-
Patients must not have received a taxane (paclitaxel, docetaxel, or protein-bound paclitaxel), platinum (cisplatin, carboplatin, or oxaliplatin), vinca alkaloid (vinblastine, vincristine, or vinorelbine), or bortezomib-based chemotherapy regimen prior to registration. (Note that while patients must not have received carboplatin in the past, patients may receive a carboplatin-containing regimen after registration as part of the docetaxel or paclitaxel regimen.)
-
Patients who can complete Patient-Reported Outcome (PRO) instruments in English or Spanish must:
- Agree to complete PROs at all scheduled assessments
- Complete the baseline PRO forms prior to registration
-
Patients with pre-existing neuropathy are eligible, including those with diabetes and neurological conditions such as multiple sclerosis or Parkinson?s disease.
-
Patients must agree to submit required specimens for defined translational medicine.
-
Patients must be offered the opportunity to submit additional optional specimens for future, unspecified translational medicine and banking. With patient?s consent, specimens must be submitted.
-
Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
-
As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
코호트 및 개입
그룹/코호트 |
개입 / 치료 |
|---|---|
|
Observational (non-study chemo, questionnaire, assessments)
Patients receive chemotherapy regimen per treating physician for 52 weeks in the absence of disease progression or unacceptable toxicity. Patients also complete questionnaires at weeks 4, 8, 12, 24 and 52. |
Given chemotherapy regimen
다른 이름들:
Functional and sensory clinician assessments Patient and physician reported responses |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants With Development of Peripheral Neuropathy
기간: Up to 24 weeks
|
Will be measured as an absolute increase of >= 8 points over the baseline chemotherapy-induced peripheral neuropathy (CIPN)-20 sensory neuropathy subscale score. Will be collected before or at the 24-week assessment.. |
Up to 24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
CIPN Symptoms
기간: Up to 52 weeks
|
Patients experiencing a treatment change attributed to CIPN symptoms |
Up to 52 weeks
|
|
Dose Changes
기간: Up to 52 weeks
|
Dose reductions, delays, and discontinuations of treatment (prior to completing the original treatment plan) |
Up to 52 weeks
|
|
Health-related Quality of Life
기간: Up to 52 weeks
|
Assessed using the Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29). The PROMIS-29 is a well validated assessment tool that offers both qualitative and quantitative measures of health-related quality of life. The PROMIS-29 includes 29 questions evaluating areas of physical function, anxiety, depression, fatigue, sleep, social functioning, and pain interference. The PROMIS-29 assesses severity levels of symptoms and their effect on the patient's functioning. |
Up to 52 weeks
|
|
Visual Analog Toxicity Score
기간: Up to 52 weeks
|
Assessed using the Visual Analog Toxicity Score. The Visual Analog Toxicity Score is a single question asking the physician to rate how the physician feels the patient's disease and treatment affects their daily life on a scale from 0 (no symptoms and no effect on life) to 10 (severe effects of treatment and patient would rather be dead). |
Up to 52 weeks
|
|
Patient Reported Symptom
기간: Up to 52 weeks
|
Assessed using the Patient Reported Symptom Burden Score. The Patient Reported Symptom Score at baseline contains one question to assess how cancer symptoms affect the patient's life (scale 0 [no burden at all] to 10 [a great burden]). At follow-up, the Symptom Burden Score contains five questions: 1) to assess burden of side effects of cancer treatment on life (scale 0 [no burden at all] to 10 [a great burden]), 2) to assess severity of side effects from cancer treatment (scale 0 [no side effects]) to 10 [side effects extremely severe and unbearable]), 3) to assess tolerability of side effects for set time periods (yes/no), 4) to assess level at which treatment would be considered intolerable (scale 0 [side effects not severe at all] to 10 [side effects extremely severe and unbearable]), and 5) to assess the burden of cancer symptoms and treatment symptoms (scale 0 [no burden at all] to 10 [a great burden]). |
Up to 52 weeks
|
|
Leisure-time Exercise Habits
기간: Up to 52 weeks
|
Assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ). The GSLTPAQ is a brief 4 item self-administered questionnaire of usual leisure-time exercise habits over a typical 7-day period. The Leisure Score Index (LSI) is calculated based on the first 3 questions. The LSI scores can be used to classify respondents into active (LSI > 24) and insufficiently active (LSI < 23) categories. |
Up to 52 weeks
|
|
Patient-Reported Outcomes
기간: Up to 52 weeks
|
Assessed using the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE [CTCAE Version 5.0]). PRO-CTCAE assesses 78 adverse events by self-report with 124 items. Each item uses a plain language term for the adverse event, the attribute of interest, and the standard recall period of "the past 7 days". |
Up to 52 weeks
|
|
National Cancer Institute-Common Terminology Criteria for Adverse Events
기간: Up to 52 weeks
|
The NCI-CTCAE is a subjective method to evaluate CIPN performed by a healthcare professional. The treating physician will grade the subject's dysesthesia, paresthesia, neuralgia, peripheral sensory neuropathy, and peripheral motor neuropathy on a scale of 0 to 5 depending on the severity. The advantage of the NCI-CTCAE is that the assessment is quick and easy for providers to perform, (8) but it is limited by the subjectivity of interpretation, lack of detail about location, type, and severity of impairment, and narrow scoring range. Participants will only be graded for the event types listed above, so these will only be reported as an outcome measure, and will not appear in the adverse events section of this report. |
Up to 52 weeks
|
|
Assess Incidence of CIPN
기간: Up to 52 weeks
|
Assessed using European Organization for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 (CIPN-20). The EORTC QLQ-CIPN20 is a 20-item questionnaire that evaluates CIPN using 3 subscales that assess sensory (9 items), motor (8 items), and autonomic (3 items) symptoms and functioning with each item measured on a 1-4 scale (1, not at all; 4, very much). The sensory subscale raw scores range from 1 to 36. The CIPN-20 subscale raw scores are linearly converted to a 0-100 scale such that a high score corresponds to a worse condition or more symptoms. |
Up to 52 weeks
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Meghna S Trivedi, SWOG Cancer Research Network
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- S1714
- UG1CA189974 (미국 NIH 보조금/계약)
- S1714 (기타 식별자: CTEP)
- NCI-2018-01568 (레지스트리 식별자: CTRP (Clinical Trial Reporting Program))
- SWOG-S1714 (기타 식별자: DCP)
- S1714 (기타 식별자: SWOG)
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .